Furthermore, insulin-treated DM was identified as a risk factor for progressing into MACE in the combined SPIRIT and COMPARE trials as was found in this register and an earlier sub-analysis of the ABSORB trials enforcing the believe that insulin-treated DM is a risk factor for EE-BRS treatment as well as for metallic DES [11, 32]. Here, INS is linked to diabetes mellitus.